A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
A phase 3 trial of TAR-210 and Gemcitabine in bladder & urothelial cancer, run by Janssen Research & Development, LLC, now recruiting.
Overview
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer is a phase 3 interventional study registered as NCT06319820 by Janssen Research & Development, LLC, with 641 participants planned, started 2024-04-18 and due to reach its primary completion in 2028-06-28. Interventions recorded: TAR-210, Gemcitabine and MMC.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Shares TAR-210, Johnson & Johnson, Bladder & urothelial cancer.
- TrialA Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
Shares Johnson & Johnson, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC
Shares Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
- TrialAn Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Shares Johnson & Johnson, Bladder & urothelial cancer and the tag pipeline.
- TrialStudy of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Shares Johnson & Johnson, Bladder & urothelial cancer and the tag pipeline.
- TrialPhase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Shares Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
- Trial9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Shares Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
- TrialStudy of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Shares Gemcitabine, Bladder & urothelial cancer and the tag pipeline.